Sepsis: Still going strong

Archives of Medical Research

Volumn 36, Issue 6, 2005, Pages 672-681

  Rangel Frausto, M Sigfrido ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Epidemiology; Sepsis; Septic shock; Treatment of sepsis

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; DROTRECOGIN; GLYCOPEPTIDE; HYDROCORTISONE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; TEICOPLANIN; UREIDOPENICILLIN DERIVATIVE; VANCOMYCIN;

ANALGESIA; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; INFECTION RATE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; RESUSCITATION; REVIEW; RISK FACTOR; SEDATION; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

HOSPITAL MORTALITY; HUMANS; INFLAMMATION; RISK FACTORS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 26444558047     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2005.06.006     Document Type: Review

References (82)

1. R.C. Bone, R.A. Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, W.A. Knaus, R.M. Schein, and W.J.l Sibbald Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee Chest 101 1992 1644 1655
2. R.P. Dellinger, J.M. Carlet, H. Masur, H. Gerlach, T. Calandra, J. Cohen, J. Gea-Banacloche, D. Keh, J.C. Marshall, M.M. Parker, G. Ramsay, J.L. Zimmerman, J.L. Vincent, and M.M. Levy Surviving Sepsis Campaign guidelines for the management of severe sepsis and septic shock Crit Care Med 32 2004 858 873
3. National Center for Health Statistics National Vital Statistics Reports. Table E: deaths and percentages of total deaths for the ten leading causes of death, by race: United States, 2001 National Center for Health Statistics 52 2003 9
4. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated cost of care Crit Care Med 29 2001 1303 1310
5. R.P. Wenzel Anti-endotoxin monoclonal antibodies: a second look N Engl J Med 326 1992 1151 1153
6. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
7. R.P. Wenzel The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? Int J Epidemiol 17 1988 225 227
8. J.E. Parrillo, N.N. Parker, C. Natanson, A.F. Suffredini, R.L. Danner, R.E. Cunnion, and F.P. Ognibene Septic shock in humans - advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy Ann Intern Med 113 1990 227 242
9. M.S. Niederman, and A.M. Fein Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical consequence Clin Chest Med 11 1990 633 656
10. R.C. Bone, C.J. Fisher Jr., T.P. Clemmer, G.J. Slotman, C.A. Metz, and R.A. Balk Sepsis syndrome: a valid clinical entity Crit Care Med 17 1989 389 393
11. R.C. Bone Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions Ann Intern Med 114 1991 332 333
12. M.S. Rangel-Frausto, D. Pittet, M. Costigan, T. Hwang, C.S. Davis, and R.P. Wenzel The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study JAMA 273 1995 117 123
13. R.C. Bone Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) Ann Intern Med 125 1996 680 687
14. R. Bellomo The cytokine network in the critically ill Anaesth Intensive Care 20 1992 288 302
15. L.C. Casety, R.A. Balk, and R.C. Bone Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome Ann Intern Med 119 1993 771 778
16. R.J. Gloris Mediators of multiple organ failure Int Care Med 16 suppl 3 1990 S192 S196
17. S. Bhakdi, T. Klonish, P. Nuber, and W. Fisher Stimulation of monokine production by lipoteichoic acids Infect Immun 59 1991 4619 4620
18. C.P. Timmerman, E. Mattsson, L. Martínez-Martinez, L. De Graaf, J.A. Van Stijp, H.A. Verbrugh, J. Verhoef, and A. Fleer Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans Infect Immun 61 1993 4167 4172
19. J.T. Frieling, J.A. Mulder, T. Hendricks, J.H. Curfs, C.J. Van der Linden, and R.W. Sauerwein Differential induction of pro and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment Antimicrob Agents Chemother 41 1997 1439 1443
20. P.M. Leppper, T.K. Held, E.M. Schneider, E. Bölke, H. Gerlach, and M. Trautmann Clinical implications of antibiotic induced endotoxin release in septic shock Intensive Care Med 28 2002 824 833
21. F. Re, and J. Strominger Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells J Biol Chem 276 2001 37692 37699
22. D.R. Meldrum Tumor necrosis factor in the heart Am J Physiol 274 1998 577 595
23. G.B. Johnson, G.J. Brunn, B. Samstein, and J.L. Platt New insights into the pathogenesis of sepsis and the sepsis syndrome Surgery 137 2005 393 395
24. C. Brun-Buisson, F. Doyon, J. Carlet, P. Dellamonica, F. Gouin, A. Lepoutre, J.C. Mercier, G. Offenstadt, and B. Regnier Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units JAMA 274 1995 968 974
25. H. Kieft, A.I.M. Hoepelman, W. Zhou, M. Rozenberg-Arska, A. Struyvenberg, and J. Verhoef The sepsis syndrome in a Dutch university hospital Arch Intern Med 153 1993 2241 2247
26. D. Pittet, S. Rangel-Frausto, N. Li, D. Tarara, M. Costigan, and R.P. Wenzel Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients Intensive Care Med 21 1995 302 309
27. Rangel-Frausto MS, Pittet D, Costigan M, Wenzel RP. Risk factors for septic shock: a matched case-control study. In: Proc 35th Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA 1995;abs J24.
28. D.W. Bates, K. Sands, E. Miller, P.N. Lanken, P.L. Hibberd, P.S. Graman, J.S. Schwartz, K. Kahn, D.R. Snydman, J. Parsonnet, R. Moore, E. Black, B.L. Johnson, A. Jha, and R. Platt Predicting bacteremia in patients with sepsis syndrome J Infect Dis 176 1997 1538 1551
29. P. Peduzzi, C. Shatney, J. Sheagren, and C. Sprung Predictors of bacteremia and gram-negative bacteremia in patients with sepsis Arch Intern Med 152 1992 529 535
30. J. Cohen, C. Brun-Buisson, A. Torres, and J. Jorgensen Diagnosis of infection in sepsis: an evidence-based review Crit Care Med 32 suppl 1 2004 S466 S494
31. M. Llewelyn, and M. Cohen Diagnosis of infection in sepsis Intensive Care Med 27 2001 S10 S32
32. Centers for Disease Control. National nosocomial infections study report. Annual summary, October 1975.
33. Centers for Disease Control Nosocomial infections surveillance, 1980-82 CDC Surveillance Summaries 32 1983 1S 16S
34. Centers for Disease Control Nosocomial infections surveillance, 1983 CDC Surveillance Summaries 33 1984 9S 22S
35. D.R. Schaberg, D.H. Culver, and R.P. Gaynes Major trends in the microbiology etiology of nosocomial infections Am J Med 91 1991 72S 75S
36. S.M. Gordon, J.M. Serkey, T.F. Keys, T. Ryan, C.A. Fatica, S.K. Schmitt, J.A. Borsh, D.M. Cosgrove, and J.P. Yared Secular trends in nosocomial bloodstream infections in a 55-bed cardiothoracic intensive care unit Ann Thorac Surg 65 1998 95 100
37. L.K. Archibald, M.O. den Dulk, K.J. Pallangyo, and L.B. Reller Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized patients in Dar es Salaam, Tanzania Clin Infect Dis 26 1998 290 296
38. S. Ponce-de-León-Rosales, F. Molinar-Ramos, G. Domínguez-Cherit, M.S. Rangel-Frausto, and V.G. Vázquez-Ramos Prevalence of infections in intensive care units in Mexico (EPIC-Mexico): a multicenter study Crit Care Med 28 2000 1316 1321
39. O. Marchetti, and T. Calandra Infections in neutropenic cancer patients Lancet 309 2002 723 725
40. P.Y. Bochud, M. Bonten, O. Marcheti, and T. Calandra Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review Crit Care Med 32 suppl 1 2004 S495 S512
41. J.M. Gatell, A. Trilla, X. Latorre, M. Almela, J. Mensa, A. Moreno, J.M. Miro, J.A. Martinez, M.T. Jimenez de Anta, and E. Soriano Nosocomial bacteremia in a large Spanish teaching hospital: analysis of factors influencing prognosis in 133 episodes Rev Infect Dis 10 1988 629 635
42. J. Bisbe, J.M. Gatell, J. Puig, J. Mallolas, J.A. Martinez, M.T. Jimenez de Anta, and E. Soriano Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing prognosis in 133 episodes Rev Infect Dis 10 1988 629 635
43. F.J. Roberts, I.W. Gere, and A. Coldman A three year study of positive blood cultures, with emphasis on prognosis Rev Infect Dis 13 1991 34 46
44. M. Hilf, V.L. Yu, J. Sharp, J.J. Zuravleff, J.A. Korvick, and R.R. Muder Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients Am J Med 87 1989 540 546
45. J.E. McGowan, M.W. Barnes, and M. Finland Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases J Infect Dis 132 1975 316 335
46. R.R. Muder, C. Brennen, M.M. Wagener, and A.M. Goetz Bacteremia in a long-term-care facility: a five-year prospective study of 163 consecutive episodes Clin Infect Dis 14 1992 647 654
47. H.F. Geerdes, D. Ziegler, H. Lode, M. Hund, A. Loehr, W. Fangmann, and J. Wagner Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989 Clin Infect Dis 15 1992 991 1002
48. J.B. Haug, S. Harthung, T. Kalager, A. Digranes, and C.O. Solberg Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome Clin Infect Dis 19 1994 246 254
49. D. Pittet, N. Li, and R.P. Wenzel Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality Eur J Infect Dis 12 1993 813 819
50. D. Pittet, B. Thievant, and R.P. Wenzel Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients Int Care Med 19 1993 265 272
51. T. Towsend, and R.P. Wenzel Nosocomial bloodstream infections in a newborn intensive care unit: a case-matched control study of morbidity, mortality and risk Am J Epidemiol 114 1981 73 80
52. S.L. Landry, D.L. Kalser, and R.P. Wenzel Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: A controlled study Am J Infect Control 17 1989 323 329
53. M.A. Martin, M.A. Pfaller, and R.P. Wenzel Coagulase-negative Staphylococcal bacteremia Ann Intern Med 110 1989 9 16
54. S.B. Wey, M. Mori, M.A. Pfaller, R.F. Woolson, and R.P. Wenzel Hospital-acquired candidemia: the attributable mortality and excess length of stay Arch Intern Med 148 1988 2642 2645
55. S.B. Wey, M. Mori, M.A. Pfaller, R.F. Woolson, and R.P. Wenzel Risk factors for hospital-acquired candidemia Arch Intern Med 149 1989 2349 2353
56. D. Pittet, D. Tarara, and R.P. Wenzel Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality JAMA 271 1994 1598 1601
57. M.B. Edmond, J.F. Ober, D.L. Weinbaum, and R.P. Wenzel Natural history and attributable morbidity and mortality of vancomycin-resistant enterococcal bacteremia Clin Infect Dis 23 1996 1234 1239
58. T.M. Perl, L.A. Dvorak, T. Hwang, and R.P. Wenzel Long-term survival and function after suspected gram-negative sepsis JAMA 274 1995 338 345
59. K.C. Sasse, E. Nauenberg, A. Long, B. Anton, H.J. Tucker, and T.W. Hu Long-term survival after intensive care unit admission with sepsis Crit Care Med 23 1995 1040 1047
60. E.J. Ziegler, J.A. McCutchan, J. Fierer, M.P. Glauser, J.C. Sadoff, H. Douglas, and A.I. Braude Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli N Engl J Med 307 1982 1225 1230
61. E.J. Ziegler, C.J. Fisher Jr., C.L. Sprung, R.C. Straube, J.C. Sadoff, G.E. Foulke, C.H. Wortel, M.P. Fink, R.P. Dellinger, and N.N. Teng Treatment of gram-negative bacteremia and septic shock with a HA-1a human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial N Engl J Med 324 1991 429 436
62. R.L. Greenman, R.M.H. Schein, M.A. Martin, R.P. Wenzel, N.R. MacIntyre, G. Emmanuel, H. Chmel, R.B. Kohler, M. McCarthy, and J. Plouffe A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis JAMA 266 1991 1097 1102
63. C.J. Fisher Jr., J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, J.C. Sadoff, E. Abraham, R.M. Schein, and E. Benjamin Treatment of septic shock with the tumor necrosis factor: FC fusion protein N Engl J Med 334 1996 1697 1702
64. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Delibant (CP-0127): results of a randomized, double-blind placebo-controlled trial JAMA 277 1997 482 487
65. E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, E. Peterson, and M. Tomlanovich Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 345 2001 1368 1377
66. A. Rhodes, and D. Bennet Early goal directed therapy: an evidence-based review Crit Care Med 32 2004 448 450
67. M.A. Freid, and K.L. Vosti The importance of underlying disease in patients with gram-negative bacteremia Arch Intern Med 121 1968 418 423
68. B.E. Kreger, D.E. Craven, and W.R. McCabe Gram negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients Am J Med 68 1980 344 355
69. R.E. Bryant, and C.E. Hood Factors affecting mortality of gram negative rod bacteremia Arch Intern Med 127 1971 120 128
70. W.R. McCabe, and G.G. Jackson Gram negative bacteremia Arch Intern Med 110 1962 92 100
71. M. Zaidi, J. Sifuentes-Osornio, A.L. Rolon, G. Vazquez, R. Rosado, M. Sanchez, J.J. Calva, and S. Ponce de Leon-Rosales Inadequate therapy and antibiotic resistance: risk factor for mortality in the intensive care unit Arch Med Res 33 2002 290 294
72. J.S. Solomkin, W.K. Fant, J.O. Rivera, and J.W. Alexander Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections Am J Med 78 1985 85 91
73. H. Dupont, C. Carbon, and J. Carlet Monotherapy with a broad spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial Antimicrob Agents Chemother 44 2000 2028 2033
74. S.R. Norby, R.G. Finch, and M. Galuser Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/ cilastatin J Antimicrob Chemother 31 1993 927 937
75. S. Methar, Dew Rep, D.J. Leaper, and E.W. Taylor A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections J Antimicrob Chemother 39 1997 631 638
76. D. Cook, and G. Guyatt Colloid use for fluid resuscitation: evidence and spin Ann Intern Med 135 2001 205 208
77. G.R. Haynes, R.J. Navickis, and M.M. Wilkes Albumin administration - what is the evidence of clinical benefit? A systematic review of randomized controlled trials Eur J Anaesthesiol 20 2003 771 793
78. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. La Rosa, J.F. Dhainaut, A. Lopez-Rodriguez, J.S. Steingrub, G.E. Garber, J.D. Helterbrand, E.W. Ely, and C.J. Fisher Efficacy and safety of recombinant human activated C protein for severe sepsis N Engl J Med 344 2001 699 704
79. US Food and Drug Administration. Product approval information-licensing action. Available at: http://www.fda.gov.cber.products.droteli112101.htm. Accessed January 15, 2005.
80. C. McCoy, and S.J. Mathews Drotrecogin alfa (recombinant human activated c protein) for the treatment of severe sepsis Clin Ther 25 2003 396 421
81. J.L. Moran, M.J. Chapman, and M.S. O'Fathartaigh Hypocortisolaemia and adrenocortical responsiveness at the onset of septic shock Intensive Care Med 20 1994 489 495
82. D. Annane, V. Seville, G. Troche, J.C. Raphael, P. Gajdos, and E. Bellissant A 3 level prognostic classification in septic shock based on cortisol levels and cortisone response to corticotrophin JAMA 283 2000 1038 1045